Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood thinner could make heart bypass safer during surgery

NCT ID NCT07514962

Disease control Sponsor: Cardiocentro Ticino Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether giving the blood thinner cangrelor through a vein during minimally invasive heart bypass surgery is safe and practical. The goal is to prevent dangerous blood clots while the patient is on the operating table. Researchers will compare 30 patients receiving cangrelor during surgery to similar patients from the past who received standard care with aspirin. The main focus is on whether cangrelor increases the risk of serious bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cangrelor (a fast-acting blood thinner given through a vein)
What this could lead to
If successful, this could make minimally invasive heart bypass surgery safer by preventing blood clots during the procedure without increasing bleeding complications.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to all patients. There is still a risk of bleeding or other complications despite careful monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes adult patients scheduled for minimally invasive direct coronary artery bypass (MIDCAB) surgery at Cardiocentro Ticino Institute, Lugano, Switzerland. Patients will be selected for either prospective cangrelor-guided MIDCAB or retrospective historical control MIDCAB under aspirin therapy. The population includes individuals with multivessel coronary artery disease requiring LIMA-LAD bypass, regardless of sex or comorbidities, who meet all inclusion and no exclusion criteria. Patients with planned concomitant PCI are excluded. This population represents real-world candidates for MIDCAB surgery under antiplatelet management protocols.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for the historical control arm: * Age ≥18 years old * CABG with IMA-LAD graft in MIDCAB technique Inclusion criteria for the prospective arm: * Age ≥18 years old * CABG with IMA-LAD graft in MIDCAB technique * Signed informed consent Exclusion criteria for the historical control arm * Administration of fibrinolytics or GP IIb/IIIa inhibitors * Previous intracranial hemorrhage * Known bleeding diathesis * Patients undergoing concomitant PCI and MIDCAB * Severe renal or liver disease * Pregnancy or breast feeding Exclusion criteria for the prospective arm * Unconsciousness * Known hypersensitivity to study drug (cangrelor) * Recent administration of fibrinolytics or GP IIb/IIIa inhibitors * Previous intracranial hemorrhage * Known bleeding diathesis * Patients undergoing concomitant PCI and MIDCAB * Severe renal or liver disease * Pregnancy or breast feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antiplatelet therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antiplatelet therapy Coronary artery disease Minimally invasive coronary revascularization surgery

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istituto Cardiocentro Ticino

    RECRUITING

    Lugano, Ch/ti, 6900, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.